This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.

Localization-related symptomatic epilepsy, complex partial, intractable난치성 뇌전증을 동반한 국소화-관련 증상성 복합부분발작 뇌전증

ICD-10 codeG40.21
Special Copayment Reduction codeV279
Synonyms / related termsIntractable temporal lobe epilepsy, complex partial seizure epilepsy, drug-resistant focal epilepsy, FCD-related epilepsy
ClassificationSevere intractable disease (Special Copayment Reduction registration criteria: 5 years)

History

Localization-related symptomatic epilepsy refers to focal epilepsy caused by an identifiable structural or lesional cause, with complex partial seizures (now "focal seizures with impaired awareness" in the ILAE 2017 classification) as the main clinical phenotype. Intractable is defined as seizure control not being achieved despite two or more appropriately chosen and prescribed antiseizure medications (ASMs).

Temporal lobe epilepsy (TLE) is the most common form in this category; in the 1950s Penfield and Jasper systematized the association between hippocampal lesions and complex partial seizures. When hippocampal sclerosis (HS) became visualizable on MRI in 1994, understanding of the etiology of TLE and prediction of surgical outcomes improved dramatically. Since the 2000s, advances in genetic diagnostic technology have revealed diverse structural substrates such as FCD (focal cortical dysplasia) and tuberous sclerosis.

ICD-10 G40.21 codes localization-related symptomatic epilepsy with intractable complex partial seizures, and it is designated as a disease eligible for the domestic Special Copayment Reduction V279, providing the benefit of reduced medical costs.

Causes

The causes of intractable localization-related symptomatic epilepsy are broadly divided into structural, metabolic, infectious, immune, and genetic categories. The most frequent structural causes are hippocampal sclerosis (HS; temporal lobe), focal cortical dysplasia (FCD; all lobes), vascular malformations (cavernous hemangioma), low-grade glioma and ganglioglioma, scars after traumatic brain injury, and sequelae of meningoencephalitis.

Metabolic causes include pyridoxine-dependent epilepsy, GLUT1 deficiency, and creatine synthesis disorders, and as immune causes, autoimmune encephalitis associated with antibodies to LGI1, CASPR2, NMDAR, and the GABA-B receptor can present as focal intractable epilepsy. A history of febrile seizures is well known as a preceding risk factor for the formation of HS.

As genetic causes, DEPDC5 (mTOR pathway) mutation is an important cause of familial focal epilepsy and is associated with structural cortical dysplasia. SCN1A (Dravet syndrome), KCNQ2/3, PCDH19, and others can also present with a focal seizure pattern.

Genetics

The weight of genetic testing is increasing in intractable localization-related symptomatic epilepsy. DEPDC5, the main causative gene of familial focal epilepsy with variable foci (FFEVF), is inherited in an autosomal dominant manner, and loss-of-function variants in the mTOR complex 1 (mTORC1)-inhibiting pathway cause focal cortical dysplasia and intractable epilepsy.

Somatic mosaic mutations of mTOR pathway-related genes (DEPDC5, NPRL2, NPRL3, TSC1, TSC2, MTOR, PIK3CA, PTEN) explain a considerable proportion of sporadic FCD type 2, and these can be detected only by direct analysis of brain tissue or ultra-deep sequencing.

In addition, variants in cerebral cortical organization genes such as SRPX2 and NRXN1 and copy number variations such as the 15q11-q13 duplication, 1q21, and 16p13 are also associated with focal epilepsy. Clinically, genetic testing is performed through whole-exome sequencing (WES) or an epilepsy panel, and even if negative, the possibility of somatic variants should be considered.

Epidemiology

The overall prevalence of epilepsy is 5-10 per 1,000 population, and focal epilepsy accounts for about 60% of the total. Of these, about 30% progress to intractable epilepsy that does not respond to two or more ASMs, and patients with intractable complex partial seizures corresponding to G40.21 are estimated at about 10-20% of all epilepsy.

Temporal lobe epilepsy is the most common form of adult intractable focal epilepsy (60-70%), and hippocampal sclerosis accounts for about 65% of the causes. The median age at onset is about 15-20 years, and the diagnostic delay averages 10-15 years, which tends to delay the timing of surgical treatment.

Based on domestic National Health Insurance claims data, intractable epilepsy patients number about 30,000-40,000 per year. For patients registered under Special Copayment Reduction (V279), the copayment rate for treatment costs is reduced to 10%, providing practical help for continuing treatment.

Pathophysiology

The core pathophysiology of intractable localization-related symptomatic epilepsy is chronic hyperexcitability within the epileptogenic zone (EZ). In hippocampal sclerosis, loss of pyramidal cells in the CA1 and CA3 regions, together with formation of excitatory recurrent synaptic circuits through mossy fiber sprouting, contributes to self-perpetuating seizure generation.

In FCD, the persistent depolarization shift of dysmorphic neurons, abnormal GABA inhibitory function, and synaptic overgrowth due to mTOR overactivation cause hyperexcitability. In particular, balloon cells in FCD type IIb are known as the main cellular substrate of hyperexcitability.

Abnormal synchronization of the hippocampus-amygdala-entorhinal cortex network is the origin of complex partial seizures, and propagation to limbic-frontal networks causes impaired consciousness. Chronic epilepsy forms a vicious cycle that reinforces epileptogenesis through neuroinflammation and overexpression of IL-1β, TNF-α, and COX-2.

Symptoms

The characteristic clinical feature of complex partial seizures is a focal seizure accompanied by altered consciousness during the seizure (decreased responsiveness). An aura such as an epigastric rising sensation, fear, déjà vu, jamais vu, olfactory or gustatory hallucinations, or visual distortion may precede it, and this is an important clue to localizing the seizure origin.

Automatisms are characteristic during seizures, and oroalimentary automatisms (lip smacking, chewing, swallowing), hand automatisms (purposeless hand movements, movements resembling buttoning), and dystonic posturing are observed. Postictal confusion, speech disturbance, memory gaps, and headache persist for several minutes to several hours.

Seizures may progress secondarily to generalized tonic-clonic seizures, in which case the risk of bodily injury increases. Status epilepticus can occur in the form of complex partial seizures (nonconvulsive SE) and is easily missed clinically. Mental health problems such as memory decline, language disorder, depression, and anxiety disorder due to repeated seizures are often present.

Signs

The presence and degree of abnormal findings on interictal neurological examination vary with the type and location of the causative lesion. In hippocampal sclerosis alone, there is generally no obvious focal neurological deficit, but learning and memory impairment from repeated seizures accumulates.

Neuropsychological testing confirms verbal (dominant hemisphere) or nonverbal (non-dominant hemisphere) memory impairment. Preoperative assessment of memory and language function is performed with the Wada test or fMRI language lateralization.

As short-term postictal neurological abnormalities, Todd paralysis, aphasia, and ipsilateral pupillary dilation may be observed. In the long-term course, ipsilateral frontal lobe functional decline, contralateral cortical atrophy, and reduced working memory are confirmed by neuroimaging and neuropsychological testing. When depression, anxiety disorder, or psychosis of epilepsy is comorbid, psychiatric consultation is needed.

Screening

Electroencephalography (EEG) is essential in the evaluation of intractable localization-related epilepsy. On scalp EEG, unilateral temporal or frontal spikes, temporal slow waves, and interictal epileptiform discharges (IEDs) suggest the hemisphere of origin. Sleep deprivation and sleep EEG increase the sensitivity of IED detection.

Long-term video-EEG monitoring (VEEG) is central to presurgical evaluation because it allows simultaneous analysis of seizure semiology and confirmation of the EEG origin. When the seizure origin cannot be determined by noninvasive evaluation, invasive EEG monitoring with intracranial electrodes (subdural grid, stereo-EEG, sEEG) is considered.

Blood tests (antiseizure medication blood levels, liver and kidney function, blood counts, electrolytes) are performed regularly for treatment monitoring and exclusion of secondary causes. An autoimmune antibody panel (LGI1, CASPR2, NMDAR, etc.) is checked on cerebrospinal fluid and serum when an immune cause is suspected.

Diagnosis

Diagnosis of intractable localization-related symptomatic complex partial seizure epilepsy requires ① confirmed persistent seizures not responding to two or more appropriate ASMs, ② EEG findings of focal origin, and ③ identification of a structural, metabolic, immune, or genetic cause.

Brain MRI applies a high-resolution epilepsy protocol (3T, 1 mm isotropic T1, FLAIR, T2 coronal oblique slices, DWI, SWI) to detect FCD, HS, vascular malformations, tumors, and so on. In MRI-negative intractable epilepsy, multiple imaging methods are integrated for evaluation, including FDG-PET (interictal hypometabolism), ictal SPECT/SISCOM (hyperperfusion at the seizure origin), and MEG (magnetoencephalography).

Comprehensive neuropsychological testing (intelligence, memory, language, executive function, attention) is needed for estimating the hemisphere of seizure origin, predicting surgical risk, and establishing a baseline. For Special Copayment Reduction registration, diagnostic confirmation by the treating neurology (or pediatric neurology) specialist, EEG and MRI results, and a prescription history of multiple ASMs are required.

Treatment

For drug treatment, carbamazepine or oxcarbazepine is the first-line drug for temporal and frontal lobe complex partial seizures. Lacosamide, lamotrigine, levetiracetam, eslicarbazepine, and cenobamate are add-on or alternative options. Benzodiazepines (clonazepam) are used short-term as add-on therapy.

Surgical treatment is the treatment with the best proven effectiveness in drug-resistant temporal lobe epilepsy. The seizure-freedom rate after anterior temporal lobectomy (ATL) or selective amygdalohippocampectomy (SAH) is about 50-80% (Engel Class I). Laser interstitial thermal therapy (LITT) is drawing attention as a minimally invasive option.

When FCD is the cause, lesionectomy or cortical resection is performed, and the seizure-freedom rate is high with complete resection. When surgical treatment is not possible, vagus nerve stimulation (VNS), responsive neurostimulation (RNS), and deep brain stimulation (DBS) of the anterior nucleus of the thalamus are considered. The ketogenic diet (KD) is used as add-on therapy in children and some adults with intractable epilepsy.

Prognosis

Intractable localization-related symptomatic epilepsy is difficult to control with drug therapy alone, and spontaneous remission is rare in long-term follow-up. Repeated seizures cause complications such as cognitive decline, accident risk, and sudden unexpected death in epilepsy (SUDEP). The age-standardized mortality ratio for SUDEP is about 24 times higher than in the general population.

In patients who underwent surgery, achieving seizure freedom (Engel Class I) markedly improves quality of life (QoL) and makes it possible to obtain a driver's license, find employment, and regain social independence. Postoperative verbal memory decline (with dominant hemisphere surgery) is the main adverse effect, and preoperative neuropsychological baselines and fMRI lateralization results are used to predict prognosis.

When seizures have persisted for more than 10 years, the prevalence of hippocampal atrophy, frontal lobe functional decline, and depression increases. Evidence is accumulating that early (within 5 years of onset) surgical evaluation and initiation of treatment are important for improving long-term prognosis.

Prevention

No primary prevention strategy for preventing the development of intractable epilepsy itself has been established. However, efforts to reduce the occurrence of secondary epilepsy are recommended through active management of prolonged febrile seizures (febrile SE), prevention of head trauma, and early treatment of central nervous system infections.

Maintaining adherence to prescribed drugs, keeping a regular sleep schedule, limiting heavy drinking, and managing seizure triggers contribute to reducing seizure frequency. Using a seizure diary app is useful for the medical team to assess ASM effect and whether the epilepsy is intractable.

Establish a seizure safety plan: this includes fall-prevention measures (lowering bed height, bathroom grab bars), a nighttime monitoring device (seizure detection device), and prescription of midazolam nasal spray. Psychosocial support: patient and family education, linkage to support groups, and vocational rehabilitation support are essential for maintaining QoL.

References

  1. Wiebe S, Blume WT, Girvin JP, Eliasziw M. A randomized, controlled trial of surgery for temporal-lobe epilepsy. N Engl J Med. 2001;345(5):311-318. PMID: 11484687
  2. Kwan P, Brodie MJ. Early identification of refractory epilepsy. N Engl J Med. 2000;342(5):314-319. PMID: 10660394
  3. Engel J Jr, McDermott MP, Wiebe S, et al. Early surgical therapy for drug-resistant temporal lobe epilepsy: a randomized trial. JAMA. 2012;307(9):922-930. PMID: 22396514
  4. Blumcke I, Thom M, Aronica E, et al. The clinicopathologic spectrum of focal cortical dysplasias: a consensus classification proposed by an ad hoc Task Force of the ILAE Diagnostic Methods Commission. Epilepsia. 2011;52(1):158-174. PMID: 21219302
  5. Scheffer IE, Berkovic S, Capovilla G, et al. ILAE classification of the epilepsies: position paper of the ILAE Commission for Classification and Terminology. Epilepsia. 2017;58(4):512-521. PMID: 28276062
  6. Lal D, Reinthaler EM, Schubert J, et al. DEPDC5 mutations in genetic focal epilepsies of childhood. Ann Neurol. 2014;75(5):788-792. PMID: 24591252
  7. Fisher RS, Acevedo C, Arzimanoglou A, et al. ILAE official report: a practical clinical definition of epilepsy. Epilepsia. 2014;55(4):475-482. PMID: 24730690
  8. de Tisi J, Bell GS, Peacock JL, et al. The long-term outcome of adult epilepsy surgery, patterns of seizure remission, and relapse: a cohort study. Lancet. 2011;378(9800):1388-1395. PMID: 22000098
  9. Téllez-Zenteno JF, Dhar R, Hernandez-Ronquillo L, Wiebe S. Long-term outcomes in epilepsy surgery: antiepileptic drugs, mortality, cognitive and psychosocial aspects. Brain. 2007;130(Pt 2):334-345. PMID: 17229797
  10. Kim JH, Kim HD, Lee JS, et al. Surgical outcome and prognostic factors of temporal lobe epilepsy in Korean patients. J Korean Neurosurg Soc. 2016;59(4):381-388. DOI: 10.3340/jkns.2016.59.4.381